News
Ligand Pharmaceuticals’ subsidiary LNHC has concluded its merger with CHRO Merger Sub to form a new entity, Pelthos Therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback